Stopping versus continuing JAK inhibitors for ulcerative colitis
Part of Digestive system clinical trials.
This study compares stopping JAK inhibitor treatment versus continuing the same dose for people with ulcerative colitis who are in deep remission. If you are doing well on your current JAK inhibitor, this trial may help you understand if you can safely stop it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ulcerative colitis for at least 6 months.
- You are at least 18 years old.
- You have been taking a JAK inhibitor (tofacitinib, upadacitinib, or filgotinib) for more than a year, and on the same dose for at least the last 6 months.
- You have been in remission (no active symptoms) for at least 6 months while on this treatment, and have not used steroids in that time.
- You do not have known risk factors for blood clots, heart problems, or cancer.
- You are willing to use effective contraception if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether it is safe to stop taking an immunosuppressant medication in older adults (60+) with ulcerative colitis that has been in remission for a long time. By stopping the drug, they hope to reduce side effects while keeping the disease under control.
This study tests whether a higher dose of upadacitinib (45 mg) can help people with ulcerative colitis whose symptoms come back while on the usual 30 mg maintenance dose. If you've lost response to your current treatment, this re-induction approach may help you get back into remission.
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
This study compares taking tofacitinib alone versus combining it with mesalamine to keep ulcerative colitis under control. If you are currently in remission, this trial may help find the best way to prevent flare-ups.
This trial tests whether people with ulcerative colitis who have been in deep remission (no signs of active disease) can safely reduce or stop their current medication. It aims to find out if careful monitoring can keep them healthy without full-dose treatment.
This trial tests two different medicines, infliximab and upadacitinib, to see which works better for people with severe ulcerative colitis that hasn't improved after 3 days of IV steroids. The goal is to find the best rescue option to help you feel better and avoid surgery.
Hear when a new Ulcerative Colitis in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.